All In Biotech

Drug Trial Radar · NCT06764862

Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis

A Randomised, Double-blind, Placebo-controlled Parallel Group Phase II Clinical Study Evaluating the Efficacy and Safety of HSK44459 Tablets in Subjects With Idiopathic Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

186

Actual

Start

Jan 17, 2025

Primary completion

Feb 12, 2026

Study completion Mar 4, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • HSK44459 dose 1Drug

    HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

  • HSK44459 dose 2Drug

    HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

  • HSK44459 dose 3Drug

    HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

  • PlaceboDrug

    Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change from baseline in forced vital capacity (FVC) at week 12Time frame: day 1 and week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.